Journal article

Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer

Michael Friedlander, Susana Banerjee, Linda Mileshkin, Clare Scott, Catherine Shannon, Jeffrey Goh

Asia-Pacific Journal of Clinical Oncology | WILEY | Published : 2016

Abstract

Olaparib is the first oral poly(ADP-ribose) polymerase inhibitor to be approved as maintenance monotherapy for treatment of patients with platinum-sensitive relapsed BRCA-mutated (BRCAm) serous ovarian cancer. This review provides practical guidance on the use of olaparib (capsule formulation) in the maintenance setting. The article focuses on the key toxicities that can arise with olaparib therapy and recommendations for their management. Nausea, vomiting, fatigue and anemia are the most commonly reported adverse events in olaparib clinical trials and are generally mild to moderate and transient in nature in most patients. Implementation of an effective and timely management plan can contro..

View full abstract

Grants

Funding Acknowledgements

Michael Friedlander has been an advisory board member for AstraZeneca and Pfizer. Jeffrey Goh has been an advisory board member and invited speaker for AstraZeneca and Roche Australia Pty Ltd, and an advisory board member for BMS Australia. Linda Mileshkin has been an advisory board member for AstraZeneca. Susana Banerjee has been an advisory board member for AstraZeneca and Clovis. Clare Scott has received personal fees and nonfinancial travel support from AstraZeneca. We thank Richard Ogilvy-Stewart PhD, from Mudskipper Business Ltd, who provided medical writing assistance funded by AstraZeneca.